# Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen

> **NCT04340401** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 25 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **RADIATION:** Intensity modulated radiotherapy
- **PROCEDURE:** Total mesorectal excision

## Key facts

- **NCT ID:** NCT04340401
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-25
- **Primary completion:** 2020-07
- **Final completion:** 2022-04
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2020-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04340401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04340401, "Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04340401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*